Impact of the CCP Test on Physician and Patient Treatment Selection

Impact of the CCP Test on Physician and Patient Treatment Selection 

Review of the abstract:

The CCP test is a validated molecular assay that assesses prostate cancer-specific disease progression and mortality risk when combined with clinicopathologic parameters.

The results from PROCEDE-1000, a large, prospective registry designed to evaluate the impact of the CCP test regarding shared treatment decision making for newly diagnosed prostate cancer patients, are presented here.

Materials and Methods: Untreated patients with newly diagnosed prostate adenocarcinoma were enrolled and the CCP test was performed on the initial prostate biopsy tissue. A set of four sequential surveys tracked changes relative to initial therapy recommendations (pre-CCP) based on clinopathologic parameters following: physician review of the CCP test result, physician/patient review of the CCP test results, and a minimum of three-months of clinical follow-up (actual treatment).

Results: 1206/1596 patients enrolled in this registry were eligible for analysis. There was a significant reduction in the treatment burden recorded at each successive evaluation (P<0.0001), with mean number of treatments per patient decreasing from 1.72 pre-CCP test to 1.16 in actual follow-up. The CCP test caused a change in actual treatment in 47.8% of patients. Of these changes, 72.1% were reductions and 26.9% were increases in treatment. For each clinical risk category, there was a significant change in treatment modality (intervention vs. non-intervention) pre-CCP to post-CCP testing (P=0.0002).

Conclusions: The CCP test has a significant impact in assisting physicians and patients reach personalized treatment decisions.

The Journal of urology. 2015 Sep 21 [Epub ahead of print]

Neal D Shore, Naveen Kella, Brian Moran, Judd Boczko, Fernando J Bianco, E David Crawford, Thaylon Davis, Kirstin M Roundy, Kristen Rushton, Charles Grier, Rajesh Kaldate, Michael K Brawer, Mark L Gonzalgo

Carolina Urologic Research Center, Myrtle Beach, SC. The Urology and Prostate Institute, San Antonio, TX. , Prostate Cancer Foundation of Chicago, Westmont, IL. , WESTMED Medical Group, Woodmere, NY. , Urological Research Network, Miami Lakes, FL. , University of Colorado at Denver, Aurora, CO. , Myriad Genetic Laboratories, Inc. , Salt Lake City, UT. , Myriad Genetic Laboratories, Inc. , Salt Lake City, UT. , Myriad Genetic Laboratories, Inc. , Salt Lake City, UT. , Myriad Genetic Laboratories, Inc. , Salt Lake City, UT. , Myriad Genetic Laboratories, Inc. , Salt Lake City, UT. , Myriad Genetic Laboratories, Inc. , Salt Lake City, UT. , University of Miami Miller School of Medicine, Miami, FL.

Read the Beyond the Abstract by Neal Shore, MD.

 Thomas E. Keane, MBBCh, FRCSI, FACS
Professor and Chairman of the Department of Urology
Medical University of South Carolina, Charleston, SC USA

BIOGRAPHY

Thomas E. Keane, MBBCh, FRCSI, FACS specializes in managing prostate, bladder, and renal cancers. An avid researcher, Dr. Keane has served as principal investigator or coinvestigator on more than 20 major clinical and preclinical studies, funded by grants from the National Institutes of Health as well as industry-funded. Much of his work focuses on innovative concepts in translational research, including utilizing human tumor xenografts to investigate the efficacy of new therapies as they relate to GU malignancies with particular reference to cytotoxic agents, sphingolipids, and boron-containing compounds. He holds a U.S. patent for BNCT in prostate cancer and sphingolipid derivatives and their use.

Dr. Keane’s research has led to publication of more than 100 articles peer-reviewed in such journals as Cancer Research, The Journal of Urology, Urologic Oncology, and the Journal of Clinical Investigation. He provides editorial services to publications ranging from Urology to the International Journal of Cancer and is coeditor of the text Glenn’s Urologic Surgery, 6th, 7th, and 8th Edition. He is an accomplished speaker, having delivered many presentations to professional societies and symposia throughout the United States and abroad.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe